BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

502 related articles for article (PubMed ID: 37277835)

  • 1. Sex hormones influence survival of patients with metastatic urothelial carcinoma undergoing immune checkpoint therapy.
    Lindner AK; Lackner F; Tymoszuk P; Barth DA; Seeber A; Kocher F; Toth B; Hochleitner M; Pichler M; Pichler R
    Biol Sex Differ; 2023 Jun; 14(1):38. PubMed ID: 37277835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sex-specific hormone changes during immunotherapy and its influence on survival in metastatic renal cell carcinoma.
    Tulchiner G; Pichler R; Ulmer H; Staudacher N; Lindner AK; Brunner A; Zelger B; Steinkohl F; Aigner F; Horninger W; Thurnher M
    Cancer Immunol Immunother; 2021 Oct; 70(10):2805-2817. PubMed ID: 33646368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. I: Plasma luteinizing hormone, follicle stimulating hormone, testosterone, estradiol, and inhibin concentrations.
    Wallace EM; Gow SM; Wu FC
    J Clin Endocrinol Metab; 1993 Jul; 77(1):290-3. PubMed ID: 8325955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of the steroid sex hormones on the LH and FSH responses to LHRH in the normal subject].
    Lemarchand-Béraud T; Reymond M; Rappoport G; Magrini G; Gomez J
    Pathol Biol (Paris); 1975 Dec; 23(10):917-22. PubMed ID: 772543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations between COVID-19 infection and sex steroid hormones.
    Cai Z; Zhong J; Jiang Y; Zhang J
    Front Endocrinol (Lausanne); 2022; 13():940675. PubMed ID: 36303865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of chronic testosterone administration in normal men: safety and efficacy of high dosage testosterone and parallel dose-dependent suppression of luteinizing hormone, follicle-stimulating hormone, and sperm production.
    Matsumoto AM
    J Clin Endocrinol Metab; 1990 Jan; 70(1):282-7. PubMed ID: 2104626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
    Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
    Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of sex on the efficacy of immune checkpoint inhibitors in kidney and urothelial cancers: a systematic review and meta-analysis.
    Yanagisawa T; Kawada T; Quhal F; Bekku K; Laukhtina E; Rajwa P; von Deimling M; Majdoub M; Chlosta M; Pradere B; Mori K; Kimura T; Schmidinger M; Karakiewicz PI; Shariat SF
    World J Urol; 2023 Jul; 41(7):1763-1774. PubMed ID: 37209143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An examination of blood steroid and gonadotropin concentrations in relation to fertility status and testicular function in men.
    Pierrepoint CG; Jenkins BM; Wilson DW; Phillips MJ; Gow JG
    Fertil Steril; 1982 Oct; 38(4):465-70. PubMed ID: 6811340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Body Composition as an Independent Predictive and Prognostic Biomarker in Advanced Urothelial Carcinoma Patients Treated with Immune Checkpoint Inhibitors.
    Martini DJ; Shabto JM; Goyal S; Liu Y; Olsen TA; Evans ST; Magod BL; Ravindranathan D; Brown JT; Yantorni L; Russler GA; Caulfield S; Goldman JM; Nazha B; Joshi SS; Kissick HT; Ogan KE; Harris WB; Kucuk O; Carthon BC; Master VA; Bilen MA
    Oncologist; 2021 Dec; 26(12):1017-1025. PubMed ID: 34342095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Annual variation in semen characteristics and plasma hormone levels in men undergoing vasectomy.
    Reinberg A; Smolensky MH; Hallek M; Smith KD; Steinberger E
    Fertil Steril; 1988 Feb; 49(2):309-15. PubMed ID: 3123279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of first-line chemotherapy regimen on survival outcomes of patients with advanced urothelial carcinoma who received second-line immune checkpoint inhibitors.
    Miron B; Handorf E; Zarrabi K; Zibelman MR; Anari F; Ghatalia P; Plimack ER; Geynisman DM
    Urol Oncol; 2022 Oct; 40(10):454.e9-454.e16. PubMed ID: 35788287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline Modified Glasgow Prognostic Score Associated with Survival in Metastatic Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors.
    Brown JT; Liu Y; Shabto JM; Martini DJ; Ravindranathan D; Hitron EE; Russler GA; Caulfield S; Yantorni LB; Joshi SS; Kissick H; Ogan K; Harris WB; Carthon BC; Kucuk O; Master VA; Bilen MA
    Oncologist; 2021 May; 26(5):397-405. PubMed ID: 33634507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of a new LH-RH analogue (D-Ser(TBU)6-EA10-LH-RH) on gonadotrophin and gonadal steroid secretion in men.
    Wiegelmann W; Solbach HG; Kley HK; Nieschlag E; Rudorff KH; Krüskemper HL
    Horm Res; 1976; 7(1):1-10. PubMed ID: 793974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Laboratory criteria for menopause in women using oral contraceptives.
    Creinin MD
    Fertil Steril; 1996 Jul; 66(1):101-4. PubMed ID: 8752618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders.
    Behre HM; Baus S; Kliesch S; Keck C; Simoni M; Nieschlag E
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2394-403. PubMed ID: 7543113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Rapidly Evolving Landscape of First-Line Targeted Therapy in Metastatic Urothelial Cancer: A Systematic Review.
    Lavoie JM; Sridhar SS; Ong M; North S; Alimohamed N; McLeod D; Eigl BJ
    Oncologist; 2021 Aug; 26(8):e1381-e1394. PubMed ID: 34028134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study).
    Bersanelli M; Buti S; Cortellini A; Bandini M; Banna GL; Pederzoli F; Farè E; Raggi D; Giannatempo P; De Giorgi U; Basso U; Losanno T; Santini D; Mucciarini C; Tucci M; Tambaro R; Farnesi A; Caffo O; Veccia A; Naglieri E; Briganti A; Procopio G; Pignata S; Necchi A
    Clin Med Insights Oncol; 2021; 15():11795549211021667. PubMed ID: 34290538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of low dose oestrogen on circulating prolactin. LH and FSH levels in post-menopausal women.
    Robyn C; Vekemans M
    Acta Endocrinol (Copenh); 1976 Sep; 83(1):9-14. PubMed ID: 989226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis.
    Mori K; Pradere B; Moschini M; Mostafaei H; Laukhtina E; Schuettfort VM; Sari Motlagh R; Soria F; Teoh JYC; Egawa S; Powles T; Shariat SF;
    Eur J Cancer; 2021 Jul; 151():35-48. PubMed ID: 33962359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.